FILTER
FILTERED INTERVIEW RESULTS
John McConnell
PRESIDENT AND CEO, VICTORIA GOLD CORP
An important story of Yukon’s gold development – the company is building the Eagle Gold mine in Canada’s North.
Robin Birchall
CEO AND DIRECTOR, GIYANI METALS CORP
The move away from internal combustion engine to electric vehicles is accelerating more rapidly than many realize.
Harry Greaves
EXECUTIVE DIRECTOR, PROSPECT RESOURCES LTD
Prospect Resources speaks to GBR about its Arcadia lithium mine in Zimbabwe.
Chris Stafford
PRESIDENT, C. J. STAFFORD & ASSOCIATES
C.J. Stafford & Associates speaks to GBR about the continual challenge of attracting talent to the mining industry with a focus on the future.
Dzingira Matenga
MANAGING DIRECTOR, DEVELOPMENT ASSETS, ERG AFRICA
GBR talks to ERG Africa about its various operations in different metals and minerals across the continent.
Ali Emiroğlu
PRESIDENT TURKISH MINERS ASSOCIATION (TMA)
GBR talks to the Turkish Miners Association about the safety culture of Turkish miners.
Joel Cavaille & Samuel Modicom
CEO, JA DELMAS & COUNTRY MANAGER, SAUDEQUIP
Saudequip supplies the Caterpillar brand across francophone West Africa and is benefitting from the region’s current boom in mining.
Edwin Ludick
MANAGING DIRECTOR, AEL INTELLIGENT BLASTING
AEL Intelligent Blasting explains to GBR how it is developing intelligent solutions for blasting across Africa and beyond.
Alicia Woods
GENERAL MANAGER, MARCOTTE MINING
GBR speaks with Marcotte Mining about how technology and innovation must drive the business.
Justine Stubbs
GROUP GENERAL MANAGER, AXIS HOUSE
Axis House provides chemicals and advise to mining companies across Africa and speaks with GBR in DRC.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
